Martin Whitely | |
---|---|
Member of the Western Australian Legislative Assembly for Roleystone | |
In office 10 February 2001 –25 February 2005 | |
Preceded by | Fred Tubby |
Succeeded by | Seat abolished |
Member of the Western Australian Legislative Assembly for Bassendean | |
In office 26 February 2005 –9 March 2013 | |
Preceded by | Clive Brown |
Succeeded by | Dave Kelly |
Personal details | |
Born | Perth Western Australia | 19 October 1959
Political party | Labor Party |
Profession | Teacher |
Martin Paul Whitely (born 19 October 1959) is a mental health researcher,author and was a Labor member of the Western Australian Legislative Assembly from February 2001 until he retired from state politics in March 2013. [1] During his parliamentary and academic research career Whitely has been a prominent critic of increasing child mental health medication prescribing rates.
Whilst still in politics Whitely wrote Speed Up and Sit Still - The Controversies of ADHD Diagnosis and Treatment (UWA Publishing 2010). [2] Since retiring from politics he completed a PhD (thesis title ADHD Policy,Practice and Regulatory Capture in Australia 1992–2012). [3] Subsequently,he has researched Australian mental health policy and practice and pharmaceutical and medical device regulation. [4] [5] His research has primarily focused on the drivers and outcomes of prescription mental health medication use by children,adolescents and young adults for ADHD and depression.
Whitely led two research projects examining the effect of relative-age within a school classroom on the probability of school-children being medicated for ADHD.
The first,Influence of birth month of Western Australian children on the probability of being treated for ADHD, was published in the Medical Journal of Australia in 2017. [6] It found that among West Australian school children aged 6–10 the youngest in class (born in June) were approximately twice as likely to take ADHD medication as their oldest classmates (born the previous July).
The second,Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions:a systematic review, published in 2019 examined 22 studies in 13 countries covering 15.4 million children. [7] It found that is the global norm for the youngest students within a school year grade to be diagnosed with and medicated for ADHD than there older classmates.
Whitely also co-authored a paper published in 2020,Look west for Australian evidence of the relationship between amphetamine‐type stimulant prescribing and meth/amphetamine use. [8] It reviewed Western Australian (WA) evidence of the relationship between prescribing amphetamine type stimulants for ADHD and the illicit use of amphetamines. It found that the non-medical use of prescription ATS by WA secondary school students is the major component of their illicit amphetamine use. It also reported that since at least 2002 WA adults have been prescribed ATS at a much higher rate than other Australian adults and WA adult illicit amphetamine use rates have consistently been among the highest in Australia.
Whitely led research published in 2020,Antidepressant Prescribing and Suicide/Self-Harm by Young Australians:Regulatory Warnings,Contradictory Advice,and Long-Term Trends. [9] It examined the Australian response to the US Food and Drug Administration's (FDA) 2004 black box warnings that antidepressant use was associated with an elevated risk of suicidal thinking and behaviours in people aged under 25.This research found that in the four years following the 2004 FDA warning there was a 31% decrease in antidepressant prescribing and a small fall in the rate of suicide by young Australians. However,from 2009 to 2018 the rates of antidepressant use and suicide by young Australians increased consistently. In 2009 there were 275 suicides by Australians aged under 25 years,in 2018 this number rose to 458.
Whitely,and his co-authors Prof Jon Juriedini and Dr Melissa Raven,concluded “correlation does not prove causation. However,given that the FDA warned that antidepressants were associated with an approximately doubled risk of suicidality relative to placebo,we are not surprised that rising dispensing rates have been accompanied by increasing youth suicide rates”.
Whitely represented the electorate of Roleystone from 2001 to 2005. Following the abolition of Roleystone,he represented the electorate of Bassendean and was the Parliamentary Secretary to the Minister for Agriculture,Food and Forestry from August 2006 until the Carpenter government lost office in September 2008. [10]
From 1995 until his election to parliament in 2001,Whitely was a secondary school teacher. During this period Western Australian ADHD child prescribing rates rose rapidly. By 2000 they were among the highest in the world and over twice the per-capita rate in of the second highest Australian state (New South Wales). [11]
In his first parliamentary speech (2001) he called for tighter ADHD prescribing controls. [12] In late December 2002 the Western Australian Health Minister Bob Kucera and Whitely jointly announced the abolition of “en bloc authorisation”which allowed “specialists to prescribe stimulants without individual patient authorisation”. [13] In August 2003 the Stimulant Regulatory Scheme began collecting detailed annual reporting of ADHD stimulant in Western Australia. Data from the Stimulant Regulatory Scheme shows after these changes the number of Western Australian children prescribing stimulants fell from 8,859 in 2004 to 5,636 in 2010,despite the state's population increasing by approximately 17%. [14] This approximates to a 46% decrease in per capita ADHD stimulant child prescribing rates over this period.
Beginning in 2011 there was a rebound in child prescribing rates. By 2017,the number of Western Australian children who received at least one prescription of an ADHD stimulant had jumped to 9,587. From 2010 until 2017 the number of children medicated increased by 70% while the state's population increased by only 15%. [15]
Whitely also campaigned to influence national (Australian) ADHD policy. He unsuccessfully sought to prevent non-stimulant ADHD medication Strattera (Atomoxetine Hydrochloride) from being added to the Pharmaceutical Benefits Scheme because of its boxed warning for increased risk of suicidality. [16] [17] Strattera was added to the PBS in 2007. Until 17 February 2018 the Therapeutic Goods Administration (TGA) had received 149 reports of adverse events. This included 78 reports of suicidal/homicidal/self-harm ideation or behaviour,with four incomplete suicide attempts (including a 7-year-old girl) and three completed suicides (including a nine-year-old boy). [18] Because adverse event reporting to the TGA by doctors is voluntary the actual number of adverse events associated with Strattera (or any medication) in Australia is unknown. [19]
He also campaigned to prevent the endorsement by the National Health and Medical Research Council (NHMRC) ADHD national treatment guidelines developed by the Royal Australian College of Physicians (RACP). The guidelines were never endorsed by the NHMRC because of concerns about conflicts of interest among guidelines panel members and the heavy reliance on research led by high-profile ADHD medication proponents with undisclosed significant conflicts of interest,most notably Professor Joseph Biederman. [20]
Whitely's self-described “at times obsessive”campaign against the use of ADHD medications by children has attracted criticism from prominent Australian psychiatrists Professors Florence Levy [21] and Alasdair Vance. [22] However,Whitely has received praise for offering a "proven public health cure...for the false epidemic of ADHD" from prominent American psychiatrist Professor Allen Frances who led the development of the DSMIV on behalf of the American Psychiatric Association. [23]
Whitely was also prominent in Australian efforts to prevent the official recognition of ‘Psychosis Risk Disorder’in the influential American Psychiatric Association's,Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM5) published in 2013. [24] Psychosis Risk Disorder (officially termed Attenuated Psychosis Syndrome) was removed from the draft of the DSM5 after its inclusion lost the support of former prominent advocates including former Australian of the Year,psychiatrist Professor Patrick McGorry. [24]
Amphetamine is a central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD),narcolepsy,and obesity. Amphetamine was discovered as a chemical in 1887 by Lazăr Edeleanu,and then as a drug in the late 1920s. It exists as two enantiomers:levoamphetamine and dextroamphetamine. Amphetamine properly refers to a specific chemical,the racemic free base,which is equal parts of the two enantiomers in their pure amine forms. The term is frequently used informally to refer to any combination of the enantiomers,or to either of them alone. Historically,it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer,and recreationally as an aphrodisiac and euphoriant. It is a prescription drug in many countries,and unauthorized possession and distribution of amphetamine are often tightly controlled due to the significant health risks associated with recreational use.
A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus,these medications are used to treat mental illnesses. These medications are typically made of synthetic chemical compounds and are usually prescribed in psychiatric settings,potentially involuntarily during commitment. Since the mid-20th century,such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization,thereby lowering the cost of mental health care. The recidivism or rehospitalization of the mentally ill is at a high rate in many countries,and the reasons for the relapses are under research.
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by executive dysfunction occasioning symptoms of inattention,hyperactivity,impulsivity and emotional dysregulation that are excessive and pervasive,impairing in multiple contexts,and otherwise age-inappropriate.
Stimulants are a class of drugs that increase the activity of the brain. They are used for various purposes,such as enhancing alertness,attention,motivation,cognition,mood,and physical performance. Some of the most common stimulants are caffeine,nicotine,amphetamines,cocaine,methylphenidate,modafinil.
Methylphenidate,sold under the brand names Ritalin and Concerta among others,is a potent central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and,to a lesser extent,narcolepsy. It is a primary medication for ADHD;it may be taken by mouth or applied to the skin,and different formulations have varying durations of effect. For ADHD,the effectiveness of methylphenidate is comparable to atomoxetine but modestly lower than amphetamines,alleviating the executive functioning deficits of sustained attention,inhibition,working memory,reaction time and emotional self-regulation.
Bupropion,formerly called amfebutamone,and sold under the brand name Wellbutrin among others,is an atypical antidepressant primarily used to treat major depressive disorder and to support smoking cessation. It is also popular as an add-on medication in the cases of "incomplete response" to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant. Bupropion has several features that distinguish it from other antidepressants:it does not usually cause sexual dysfunction,it is not associated with weight gain and sleepiness,and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue. Bupropion,particularly the immediate release formulation,carries a higher risk of seizure than many other antidepressants,hence caution is recommended in patients with a history of seizure disorder.
Dextroamphetamine (INN:dexamfetamine) is a potent central nervous system (CNS) stimulant and enantiomer of amphetamine that is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used as an athletic performance and cognitive enhancer,and recreationally as an aphrodisiac and euphoriant. Dextroamphetamine is generally regarded as the prototypical stimulant.
Developmental disorders comprise a group of psychiatric conditions originating in childhood that involve serious impairment in different areas. There are several ways of using this term. The most narrow concept is used in the category "Specific Disorders of Psychological Development" in the ICD-10. These disorders comprise developmental language disorder,learning disorders,developmental coordination disorders,and autism spectrum disorders (ASD). In broader definitions,attention deficit hyperactivity disorder (ADHD) is included,and the term used is neurodevelopmental disorders. Yet others include antisocial behavior and schizophrenia that begins in childhood and continues through life. However,these two latter conditions are not as stable as the other developmental disorders,and there is not the same evidence of a shared genetic liability.
A paradoxical reaction is an effect of a chemical substance,such as a medical drug,that is opposite to what would usually be expected. An example of a paradoxical reaction is pain caused by a pain relief medication.
Atomoxetine,sold under the brand name Strattera,is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD) and,to a lesser extent,cognitive disengagement syndrome. It may be used alone or along with psychostimulants. It enhances the executive functions of self-motivation,sustained attention,inhibition,working memory,reaction time and emotional self-regulation. Use of atomoxetine is only recommended for those who are at least six years old. It is taken orally. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate.
Adderall and Mydayis are trade names for a combination drug called mixed amphetamine salts containing four salts of amphetamine. The mixture is composed of equal parts racemic amphetamine and dextroamphetamine,which produces a (3:1) ratio between dextroamphetamine and levoamphetamine,the two enantiomers of amphetamine. In terms of base,rather than salts,the ratio is 3.15:1 for dextro- to levoamphetamine. Both enantiomers are stimulants,but differ enough to give Adderall an effects profile distinct from those of racemic amphetamine or dextroamphetamine,which are marketed as Evekeo and Dexedrine/Zenzedi,respectively. MAS is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used illicitly as an athletic performance enhancer,cognitive enhancer,appetite suppressant,and recreationally as a euphoriant. It is a central nervous system (CNS) stimulant of the phenethylamine class.
Dexmethylphenidate,sold under the brand name Focalin among others,is a potent central nervous system (CNS) stimulant used to treat attention deficit hyperactivity disorder (ADHD) in those over the age of five years. It is taken by mouth. The immediate release formulation lasts up to five hours while the extended release formulation lasts up to twelve hours. It is the more active enantiomer of methylphenidate.
Adult Attention Deficit Hyperactivity Disorder is the persistence of attention deficit hyperactivity disorder (ADHD) into adulthood. It is a neurodevelopmental disorder,meaning impairing symptoms must have been present in childhood,except for when ADHD occurs after traumatic brain injury. Specifically,multiple symptoms must be present before the age of 12,according to DSM-5 diagnostic criteria. The cutoff age of 12 is a change from the previous requirement of symptom onset,which was before the age of 7 in the DSM-IV. This was done to add flexibility in the diagnosis of adults. ADHD was previously thought to be a childhood disorder that improved with age,but recent research has disproved this. Approximately two-thirds of childhood cases of ADHD continue into adulthood,with varying degrees of symptom severity that change over time and continue to affect individuals with symptoms ranging from minor inconveniences to impairments in daily functioning.
Child psychopathology refers to the scientific study of mental disorders in children and adolescents. Oppositional defiant disorder,attention-deficit hyperactivity disorder,and autism spectrum disorder are examples of psychopathology that are typically first diagnosed during childhood. Mental health providers who work with children and adolescents are informed by research in developmental psychology,clinical child psychology,and family systems. Lists of child and adult mental disorders can be found in the International Statistical Classification of Diseases and Related Health Problems,10th Edition (ICD-10),published by the World Health Organization (WHO) and in the Diagnostic and Statistical Manual of Mental Disorders,Fifth Edition (DSM-5),published by the American Psychiatric Association (APA). In addition,the Diagnostic Classification of Mental Health and Developmental Disorders of Infancy and Early Childhood is used in assessing mental health and developmental disorders in children up to age five.
The Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP),also known as the Poisons Standard for short,is an Australian legislative instrument produced by the Therapeutic Goods Administration (TGA). Before 2010,it was known as the Standard for the Uniform Scheduling of Drugs and Poisons (SUSDP). The SUSMP classifies drugs and poisons into different Schedules signifying the degree of control recommended to be exercised over their availability to the public. As of 2024,the most recent version is the Therapeutic Goods Instrument 2024.
Guanfacine,sold under the brand name Tenex (immediate-release) and Intuniv (extended-release) among others,is an oral alpha-2a agonist medication used to treat attention deficit hyperactivity disorder (ADHD) and high blood pressure. Guanfacine is FDA-approved for monotherapy treatment of ADHD,as well as being used for augmentation of other treatments,such as stimulants. Guanfacine is also used off-label to treat tic disorders,anxiety disorders,and post-traumatic stress disorder (PTSD).
Despite the scientifically well-established nature of attention deficit hyperactivity disorder (ADHD),its diagnosis,and its treatment,each of these has been controversial since the 1970s. The controversies involve clinicians,teachers,policymakers,parents,and the media. Positions range from the view that ADHD is within the normal range of behavior to the hypothesis that ADHD is a genetic condition. Other areas of controversy include the use of stimulant medications in children,the method of diagnosis,and the possibility of overdiagnosis. In 2009,the National Institute for Health and Care Excellence,while acknowledging the controversy,stated that the current treatments and methods of diagnosis are based on the dominant view of the academic literature.
Lisdexamfetamine,sold under the brand names Vyvanse and Elvanse among others,is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. Lisdexamfetamine is taken by mouth. Its effects generally begin within two hours and last for up to 14 hours. In the United Kingdom,it is usually less preferred to methylphenidate for the treatment of children.
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD. Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents,psychological or behavioral approaches,combined pharmacological and behavioral approaches,cognitive training,neurofeedback,neurostimulation,physical exercise,nutrition and supplements,integrative medicine,parent support,and school interventions. Based on a systematic literature review and meta analysis conducted in 2024,only FDA-approved medications and psychosocial interventions have been shown to improve core ADHD symptoms compared to control groups.
Amphetamine type stimulants (ATS) are a group of synthetic drugs that are chemical derivatives of the parent compound alpha-methylphenethylamine,also known as amphetamine. Common ATS includes amphetamine,methamphetamine,ephedrine,pseudoephedrine,3,4-methylenedioxymethamphetamine (MDMA),3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxyethylamphetamine (MDEA). ATS when used illicitly has street names including ice,meth,crystal,crank,bennies,and speed. Within the group of amphetamine-type stimulants,there are also prescription drugs including mixed amphetamine salts,dextroamphetamine,and lisdexamfetamine.